Results 231 to 239 of about 29,030 (239)

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Annals of Neurology, 2011
Clas Malmeström, Tomas Olsson, Fredrik Piehl   +2 more
exaly  

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Lancet Neurology, The, 2017
Tomas Kalincik, J William L Brown, Neil P Robertson   +2 more
exaly  

Immune surveillance in multiple sclerosis patients treated with natalizumab

Annals of Neurology, 2006
Bernhard Hemmer, Olaf Stüve
exaly  

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Multiple Sclerosis Journal, 2012
Per Soelberg Sørensen, Antonio Bertolotto, Eva Kubala Havrdova   +2 more
exaly  

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

Journal of Neurology, Neurosurgery and Psychiatry, 2014
Helmut Butzkueven, Ludwig Kappos, Maria Trojano   +2 more
exaly  

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

Annals of Neurology, 2015
Tomas Kalincik, Tim Spelman, Vilija G Jokubaitis   +2 more
exaly  

Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy

Annals of Neurology, 2012
Diego Cadavid, Massimo Filippi
exaly  

Extended interval dosing of natalizumab in multiple sclerosis

Journal of Neurology, Neurosurgery and Psychiatry, 2016
exaly  

Natalizumab

Reactions Weekly
openaire   +1 more source